Miquel V. Lozano

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 193 publications

Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.

Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.

Journal: Journal for immunotherapy of cancer

Published: July 08, 2026

Late onset non-infectious pulmonary complications and pre-transplant pulmonary function as prognostic factors in allo-HCT using post-transplant cyclophosphamide.

Late onset non-infectious pulmonary complications and pre-transplant pulmonary function as prognostic factors in allo-HCT using post-transplant cyclophosphamide.

Journal: Frontiers in immunology

Published: May 07, 2026

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Journal: Frontiers in immunology

Published: April 10, 2026

Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence flow cytometry.

Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence flow cytometry.

Journal: Clinical chemistry and laboratory medicine

Published: March 25, 2026

Collection efficiency of hematopoietic cells by apheresis after mobilization in a single centre: Analysis of the last 15 years.

Collection efficiency of hematopoietic cells by apheresis after mobilization in a single centre: Analysis of the last 15 years.

Journal: Vox sanguinis

Published: February 05, 2026

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Journal: Blood advances

Published: January 15, 2026

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Journal: Therapeutic advances in neurological disorders

Published: January 09, 2026

Celebrating 70 years of Vox Sanguinis.

Celebrating 70 years of Vox Sanguinis.

Journal: Vox sanguinis

Published: December 05, 2025

Obinutuzumab for B-cell depletion prior to kidney transplant in a highly sensitized patient with anaphylactic reaction to rituximab.

Obinutuzumab for B-cell depletion prior to kidney transplant in a highly sensitized patient with anaphylactic reaction to rituximab.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Published: October 30, 2025

Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience.

Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience.

Journal: Leukemia & lymphoma

Published: October 17, 2025

Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.

Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.

Journal: British journal of haematology

Published: October 01, 2025

EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura.

EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura.

Journal: Frontiers in immunology

Published: September 07, 2025

Showing 1-12 of 193

Last Updated: 09/26/2026